ABOUT US
About SML Biopharm
SML Biopharm Co., Ltd. is a pioneering company at the forefront of mRNA vaccine and therapeutic development. Established in 2021, we focus on next-generation cancer vaccines and treatments for various diseases, utilizing cutting-edge mRNA platforms and advanced lipid nanoparticle (LNP) drug delivery systems, which gained global attention during the COVID-19 pandemic.
Our leadership team consists of Key Opinion Leaders (KOLs) with over 30 years of experience in vaccine research, development, and commercialization, with extensive expertise in antibody and virus. With a strong foundation in licensing and research, SML Biopharm is dedicated to becoming a global leader in the mRNA-based vaccine and therapeutics field.
We have already achieved significant milestones, securing multiple patents for our proprietary mRNA expression platform and LNP delivery system. Additionally, we are advancing a robust pipeline targeting a wide range of diseases. Looking ahead, we aim to expand our technology to address rare and infectious diseases, remaining committed to promoting a healthier future for all.
History
Our big moments
SML Biopharm Established
(Faculty Startup in the Department of Biomedical Sciences at Catholic University of Korea)
Company - Affiliated Research Laboratory Established at Catholic University of Korea
Seed Funding from Samkwang Labtree Co. Ltd. Secured
Venture Business Status Certified
Series A Funding from Meritz Securities Secured
New headquarter and In-House Research Center Established at M Cluster by Gwangmyeong Station
Government Grant Selected (KDCA)
SFTS Immune Candidate Non-clinical and Sample Production Condition Establishment
Grant Selected Top 1000+ Next-Generation Startups
(Ministry of SMEs and Startups)
Government Grant Selected (KDCA)
Preclinical Sample Production and Evaluation for Securing SFTS therapeutic candidate substance
Opening of a branch office in Cheongju, Chungcheongbuk-do
Government Grant Selected (Ministry of Health and Welfare)
Development of mRNA-Based Antibody Therapeutics for Severe Fever with Thrombocytopenia Syndrome (SFTS)
Selection of Chungbuk Advanced Regenerative Bio Global Innovation Special Zone Project Operator
Chungcheongbuk-do, Republic of Korea
Government Grant Selected (KDCA)
Support Program for Developing mRNA Vaccines in Preparation for a Pandemic
